Impact of GLP-1 Receptor Agonist Use in Patients With Steatotic Liver Disease and Type 2 Diabetes: A Retrospective Cohort Study
Journal of Pharmacy Practice · 2024
DOI: 10.1177/08971900241253661 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of Pharmacy Practice, 2024. Verfasst von Marci Wood und 6 weiteren Autor:innen. Beteiligte Einrichtung: The University of Vermont Medical Center, Burlington, VT, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Non-alcoholic Fatty Liver Disease, Hypoglycemic Agents, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) help manage type 2 diabetes (T2DM) and may have efficacy in steatotic liver disease.
Objective
To determine the prevalence and clinical impact of GLP-1 RA use in patients with T2DM and liver disease.
Methods
This was a retrospective study of adult patients with T2DM and nonalcoholic fatty liver disease (NAFLD), nonalcoholic fatty liver (NAFL), or nonalcoholic steatohepatitis (NASH) between 1/1/21-12/31/21. Patients with hepatitis B or C, or on pioglitazone were excluded. Eligible patients treated with a GLP-1 RA were compared to controls. The primary outcome was change in Fibrosis-4 (FIB-4) score, with NAFLD Fibrosis Score (NFS) as a secondary outcome. Follow-up scores were calculated from labs within 3 to 15 months after baseline.
Results
Of 242 eligible patients, 79 patients (32.6%) were treated with a GLP-1 RA. At baseline, FIB-4 score was lower and NFS was higher in the GLP-1 RA group vs controls (1.80 vs 2.33; P = .101, .36 vs −.47, P < .001; respectively). At follow up, FIB-4 score decreased to 1.77 in the GLP-1 RA group and increased to 2.71 in controls (P = .045). Follow up NFS was stable in the GLP-1 RA group and increased in the control group (.36 vs −.43; P = .308).
Conclusion
Patients treated with GLP-1 RAs had less evidence of liver fibrosis progression compared to no treatment, although the differences were small. These results suggest that treatment with GLP-1 RAs may have clinical impact on slowing liver fibrosis, however results should be confirmed in a larger, more diverse sample.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The University of Vermont Medical Center, Burlington, VT, USA.
- Department of Medicine Quality Program, University of Vermont Larner College of Medicine, Burlington, VT, USA.
- Ambulatory Clinical Pharmacist- Endocrinology, Yale New Haven Hospital, New Haven, CT, USA.
- Division of Gastroenterology and Hepatology, Harvard Medical School, Boston, Beth Israel Deaconess Medical Center, MA, USA.
- Division of Endocrinology, Diabetes and Osteoporosis, The University of Vermont Larner College of Medicine, Burlington, VT USA.
ORCID-Profile: Marci Wood, Amanda G Kennedy
Zitieren
APA
Wood, M., Kennedy, A. G., Khan, S., Hitt, J. R., Davis, K., Reddy, S. S., & Gilbert, M. P. (2024). Impact of GLP-1 Receptor Agonist Use in Patients With Steatotic Liver Disease and Type 2 Diabetes: A Retrospective Cohort Study. Journal of Pharmacy Practice. https://doi.org/10.1177/08971900241253661
Vancouver
Wood M, Kennedy AG, Khan S, Hitt JR, Davis K, Reddy SS, et al. Impact of GLP-1 Receptor Agonist Use in Patients With Steatotic Liver Disease and Type 2 Diabetes: A Retrospective Cohort Study. Journal of Pharmacy Practice. 2024. doi:10.1177/08971900241253661
BibTeX
@article{Wood2024,
author = {Wood, Marci and Kennedy, Amanda G and Khan, Sidra and Hitt, Juvena R and Davis, Kayla and Reddy, Sheela S and Gilbert, Matthew P},
title = {Impact of GLP-1 Receptor Agonist Use in Patients With Steatotic Liver Disease and Type 2 Diabetes: A Retrospective Cohort Study},
journal = {Journal of Pharmacy Practice},
year = {2024},
doi = {10.1177/08971900241253661}
}
EUVIMED